Search the Newsreel

AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised

Amneal Pharmaceuticals AMRX reported second-quarter 2026 adjusted earnings of 30 cents per share, which beat the Zacks Consensus Estimate of 24 cents. Earnings increased 20% year over year, driven by strong performance across the company's three business segments. Total revenues of $796 million in …

Omnicom (OMC) Stock Drops As Profit Strength Meets Integration Strain

Omnicom Group (OMC) shares dropped despite strong Q2 2026 earnings, which showed significant profit growth and increased margins, driven by higher-quality work. The company's integration efforts for the Interpublic deal and AI-led Omni platform are contributing to this strength. However, investor concerns persist due …

OmniAb, Inc. Revenue Breakdown – NASDAQ:OABIW

OmniAb, Inc. (NASDAQ:OABIW) generated $18.67 million in revenue last year, with its top-performing segment, License and Milestone, contributing $9.77 million. This is a decrease from $13.87 million in the previous year for the same segment. The United States was the primary source of revenue, …

Omnicell Inc (OMCL) (Q2 2026) Earnings Call Highlights: Strong Profitability and Strategic Wins ...

Omnicell Inc. (OMCL) reported strong Q2 2026 results with revenues at the high end of guidance and EPS well above expectations, driven by favorable revenue mix and cost management. Despite this, the company revised its full-year product bookings guidance to a wide range due …

Erie Indemnity: Q2 Earnings Snapshot

Erie Indemnity Reports Second Quarter 2026 Results

AMN Healthcare Services Inc (AMN) Valuation: PE, PB & Fair Value Analysis

AMN Healthcare Services Inc (AMN) has a current valuation score of 9.09, placing it 9th out of 75 in the Healthcare Providers & Services industry. The company's P/E ratio is -39.20, which is significantly below its recent high and slightly above its recent low. …

Stronger Q2 Results And Higher 2026 Guidance Might Change The Case For Investing In Omnicell (OMCL)

Omnicell (OMCL) reported stronger Q2 2026 results with increased revenue and net income, alongside improved full-year 2026 revenue guidance of US$1.23 billion–US$1.25 billion. This updated outlook provides clearer insights into the company's near-term growth, potentially reshaping its investment narrative. Despite the positive guidance, investors …

Vuzix CEO and CFO to discuss June-quarter results Aug. 13

Vuzix (NASDAQ: VUZI) announced that its CEO, Paul Travers, and CFO, Grant Russell, will host a conference call on August 13, 2026, at 4:30 PM ET to discuss the company's second-quarter 2026 operating results and provide a business update. Investors can access the call …

Amneal projects 2026 revenue of $3.1B-$3.2B while raising capex to about $150M

Earnings Call Insights: Amneal Pharmaceuticals (AMRX) Q2 2026 MANAGEMENT VIEW * "Amneal is in the midst of the most transformative period in our company's history," said (Co-Founder, Co-CEO, President & Director Chirag Patel), adding the company is "growing as one of the America's leading …

Vuzix Schedules Conference Call to Discuss Second Quarter 2026 Financial Results and Business Update

Vuzix Corporation announced it will host a conference call on August 13, 2026, at 4:30 PM ET to discuss its second-quarter 2026 financial results and provide a business update. CEO Paul Travers and CFO Grant Russell will participate. The company, a leading supplier of …

OMC Q2 Deep Dive: Omnicom’s Organic Growth and Integration Drive Amid Margin Pressures

OMC Q2 Deep Dive: Omnicom's Organic Growth and Integration Drive Amid Margin Pressures Global advertising giant Omnicom Group (NYSE:OMC) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 63.4% year on year to $6.56 billion. Its non-GAAP profit of $2.65 …

Citigroup Adjusts Omnicom Group Price Target to $100 From $105, Maintains Buy Rating

Citigroup has revised its price target for Omnicom Group (OMC) to $100, down from the previous $105, while retaining a "Buy" rating on the stock. This adjustment reflects a recent series of analyst target changes for Omnicom, including updates from Wells Fargo, Goldman Sachs, …

OMC Maintains Overweight Rating by Wells Fargo -- Price Target R

Wells Fargo has maintained an "Overweight" rating on Omnicom Group (OMC) and raised its price target from $91.00 to $93.00, signaling continued bullish sentiment. GuruFocus assesses OMC as 17.8% undervalued with a GF Value™ of $93.65 and a strong GF Score™ of 85/100, despite …

GUIDANCE: (OMCL) Omnicell, Inc. Expects Q3 Adjusted EPS Range $0.35 - $0.43

Omnicell, Inc. (OMCL) has issued guidance for its third-quarter adjusted EPS, anticipating a range of $0.35 to $0.43. This guidance provides investors with an outlook on the company's expected financial performance for the upcoming quarter.

Earnings call transcript: Amneal tops Q2 2026 estimates, but shares slip

Amneal Pharmaceuticals reported stronger-than-expected Q2 2026 earnings and revenue, with adjusted EPS at $0.30 and revenue at $796.2 million, beating analyst estimates. Despite the strong performance and raised full-year guidance, the stock saw a slight premarket dip, potentially due to its proximity to its …

Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Amneal Pharmaceuticals (AMRX) reported revenue of $796.2 million, up 9.9% over the same period last year. EPS came in at $0.30, compared to $0.25 in the year-ago quarter. The reported revenue represents a surprise of +3.7% over the …

Omnicell Announces Second Quarter 2026 Financial Results

Omnicell, Inc. reported solid financial results for the second quarter of 2026, with total revenues of $312 million, a 7% increase from the previous year. The company saw a significant improvement in GAAP net income and non-GAAP net income per diluted share, partly due …

Omnicom (OMC) Stock Looks Stretched On Its 38% Five Year Run

Omnicom Group (OMC) stock has delivered a 38.0% total return over the past five years, but its current valuation, with a P/E of 60.3x, appears stretched compared to the Media industry average of 21.6x and its Fair Ratio of 29.7x. While recent positive news …

Omnicell’s (NASDAQ:OMCL) Q2 CY2026: Beats On Revenue But Stock Drops On Weak Guidance

Omnicell (NASDAQ:OMCL) reported Q2 CY2026 earnings, beating Wall Street's revenue and EPS estimates with sales up 7.4% year-on-year to $312.2 million and non-GAAP EPS of $0.94. Despite the Q2 beat and raised full-year EBITDA and EPS guidance, the stock dropped 5.6% due to weaker-than-expected …

Omnicell (OMCL) Q2 Earnings and Revenues Top Estimates

Omnicell (OMCL) reported Q2 earnings of $0.94 per share, significantly exceeding the Zacks Consensus Estimate of $0.48, and revenues of $312.21 million, also topping estimates. Despite these strong results, Omnicell shares have fallen 8.6% year-to-date, contrasting with the S&P 500's 6.9% gain. The company …

Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Why is Omnicell stock rallying today?

Omnicell stock initially surged after reporting strong Q2 2026 earnings, significantly beating analyst estimates for both EPS and revenue. However, the rally was short-lived as the company's Q3 and full-year guidance fell below market expectations, leading to a subsequent pullback and erasing most of …

Earnings Flash (OMCL) Omnicell, Inc. Posts Q2 Adjusted EPS $0.94 per Share, vs. FactSet Est of $0.47

Omnicell, Inc. (OMCL) announced its Q2 adjusted earnings per share (EPS) of $0.94, significantly surpassing the FactSet estimate of $0.47. The company's Q2 revenue also exceeded expectations, reporting $312.2 million against an estimated $310.2 million. Omnicell further provided a Q3 revenue outlook ranging from …

Omnicell (NASDAQ: OMCL) Q2 profit jumps as 2026 guidance raised

Omnicell (NASDAQ: OMCL) reported strong second-quarter 2026 results, with total revenues up 7% to $312 million and GAAP net income increasing to $24 million. The company raised its full-year 2026 non-GAAP EBITDA and non-GAAP EPS guidance and tightened its revenue outlook. The positive results …

Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9%

Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9% Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 9.9% year on year to $796.2 million. The company's full-year revenue guidance of $3.15 billion …

Amneal: Q2 Earnings Snapshot

Why Omnicom Group (OMC) Stock Is Trading Lower Today

Why Omnicom Group (OMC) Stock Is Trading Lower Today What Happened? Shares of global advertising giant Omnicom Group (NYSE:OMC) fell 3.7% in the afternoon session after its second-quarter 2026 earnings report revealed a significant miss on profitability that overshadowed strong revenue growth. While the …

Vuzix (NASDAQ:VUZI) Stock Passes Below Two Hundred Day Moving Average - Here's What Happened

Vuzix (NASDAQ:VUZI) stock recently fell below its two-hundred-day moving average, trading at $2.14 with a volume of over 1 million shares. This comes after analyst downgrades, including a "sell" rating from Wall Street Zen and Weiss Ratings, contributing to an average "Hold" rating from …

Amneal Pharmaceuticals (AMRX) Wins FDA Nod For Iohexol, Is The Upside Already Priced In?

Amneal Pharmaceuticals (AMRX) recently received FDA approval for additional strengths and vial sizes of its iohexol injection, boosting its product portfolio and contributing to strong share price momentum. While analysts consider the stock about 5% overvalued with a fair value of $18.25, Simply Wall …

Erie Indemnity (ERIE) Earnings Date and Reports 2026 $ERIE

Omnicell Q2 2026 Revenue Rises 7 Percent to $312 Million

ERIE|Erie Indemnity Co|Price:252.580|Chg%:-1.480

Erie Indemnity Q2 Net Income Rises to $180.3 Million

ERIE INDEMNITY ($ERIE) Releases Q2 2026 Earnings

Erie Indemnity earnings on deck: Can insurer bounce back?